Duration of HCV infection as a predictor of nonresponse to interferon

[1]  T. Layden,et al.  Clinical and histologic predictors of response to interferon-α in patients with chronic hepatitis C viral infection , 1994, Digestive Diseases and Sciences.

[2]  K. Yoshioka,et al.  Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C , 1994, Digestive Diseases and Sciences.

[3]  N. Hayashi,et al.  Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer , 1994, Digestive Diseases and Sciences.

[4]  N. Villanova,et al.  Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: Gamma GT levels predictive for response , 1994, Digestive Diseases and Sciences.

[5]  T. Tsuji,et al.  Prediction of interferon effect in chronic hepatitis C by both quantification and genotyping of HCV-RNA , 1994, Digestive Diseases and Sciences.

[6]  N. Enomoto,et al.  Variations in the core region of hepatitis C virus genomes in patients with chronic hepatitis , 2005, Archives of Virology.

[7]  R. Bruno,et al.  Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. , 1996, Journal of hepatology.

[8]  P. Simmonds,et al.  Implications of variations of "conserved" regions of hepatitis C virus genome , 1995, The Lancet.

[9]  A. Craxì,et al.  Host and viral features in chronic HCV infection: relevance to interferon responsiveness. , 1995, Research in virology.

[10]  Ding‐Shinn Chen,et al.  Quasispecies of Hepatitis C Virus and Genetic Drift of the Hypervariable Region in Chronic Type C Hepatitis , 1995 .

[11]  A. Weiner.  Genetic drift in the hypervariable region 1 of the viral genome in persistent hepatitis C virus infection , 1995 .

[12]  N. Enomoto,et al.  Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment , 1995, Hepatology.

[13]  A. Weiner.  Humoral response to linear B cell epitopes in the amino terminus of the hepatitis C virus envelope glycoprotein gp72 (E2): Role in protective immunity still unknown , 1995, Hepatology.

[14]  M. Lai,et al.  Early interferon therapy and abortion of posttransfusion hepatitis C viral infection. , 1995, Journal of clinical gastroenterology.

[15]  M. Lai,et al.  Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis. , 1995, The Journal of infectious diseases.

[16]  N. Enomoto,et al.  Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.

[17]  Z. Halpern,et al.  Post-transfusion etiology and non-cirrhotic histology improve the remission rate of chronic hepatitis C during interferon treatment. , 1995, Israel journal of medical sciences.

[18]  Toshio Suzuki,et al.  Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon α2a therapy , 1995, Journal of medical virology.

[19]  N. Hayashi,et al.  Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C , 1995 .

[20]  H. Bonkovsky,et al.  Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. , 1995, American journal of clinical pathology.

[21]  E. Schiff,et al.  Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. , 1995, Gastroenterology.

[22]  A. Hughes,et al.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Garson,et al.  Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C , 1995, Journal of medical virology.

[24]  H. Thomas,et al.  Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. , 1995, Gut.

[25]  P. Simmonds.  Variability of hepatitis C virus , 1995, Hepatology.

[26]  R. Shayiq,et al.  High dose interferon alpha-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response. , 1995, The American journal of gastroenterology.

[27]  C. Bréchot,et al.  The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. , 1995, Gastroenterology.

[28]  Stephen J. Williams,et al.  Interferon alfa for chronic active hepatitis B , 1995, The Medical journal of Australia.

[29]  C. Girelli,et al.  IRON OVERLOAD AND RESPONSE TO ?-INTERFERON IN CHRONIC HEPATITIS C. , 1995 .

[30]  S. Kashiwagi,et al.  A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. , 1994, The American journal of gastroenterology.

[31]  M. Mizokami,et al.  Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon‐α therapy in Japanese patients with chronic hepatitis C , 1994, Journal of medical virology.

[32]  N. Enomoto,et al.  Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. , 1994, Virology.

[33]  M. Omata,et al.  Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. , 1994, Gastroenterology.

[34]  N. Enomoto,et al.  Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. , 1994, The Journal of general virology.

[35]  K. Chayama,et al.  Factors predictive of response to interferon‐α therapy in hepatitis C virus infection , 1994, Hepatology.

[36]  I. Kurelac,et al.  The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha , 1994, Infection.

[37]  A. Craxì,et al.  Interferon‐α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response , 1994 .

[38]  Y. Wang,et al.  Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C , 1994, Journal of medical virology.

[39]  P. Simmonds,et al.  Hepatitis C serotype and response to interferon therapy. , 1994, The New England journal of medicine.

[40]  N. Enomoto,et al.  Sequential change of the hypervariable region of the hepatitis C virus genome in acute infection , 1994, Journal of medical virology.

[41]  P. Lampertico,et al.  A multicenter randomized controlled trial of recombinant interferon‐α2b in patients with acute transfusion‐associated hepatitis C , 1994, Hepatology.

[42]  P. Simmonds,et al.  COMMUNITY-ACQUIRED CHRONIC HEPATITIS-C IN AN AREA OF HIGH SEROTYPE-1 ENDEMICITY - INTERFERON FOR 6 OR 12 MONTHS , 1994 .

[43]  M. Kohara,et al.  Hepatitis C virus serotype II responds more favorably to interferon-α therapy , 1994 .

[44]  W. Irish,et al.  Response to interferon α therapy is influenced by the iron content of the liver , 1994 .

[45]  C. Chan,et al.  A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. , 1994, Journal of hepatology.

[46]  N. Enomoto,et al.  Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene. , 1994, Journal of hepatology.

[47]  J. Prieto,et al.  Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. , 1994, Journal of hepatology.

[48]  G. Davis.  Prediction of response to interferon treatment of chronic hepatitis C. , 1994, Journal of hepatology.

[49]  L. Serfaty,et al.  Factors predictive of the response to interferon in patients with chronic hepatitis C. , 1994, Journal of hepatology.

[50]  J. Prieto,et al.  Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. , 1993, Gut.

[51]  P. Reynier,et al.  Hepatitis C virus genotypes in chronic hepatitis and response to interferon-alpha therapy. , 1993, The Journal of infectious diseases.

[52]  H. Ali,et al.  Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study. , 1993, Journal of hepatology.

[53]  S. Riestra,et al.  Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C. , 1993, Gut.

[54]  A. Hatzakis,et al.  Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. , 1993, Gut.

[55]  M. Petroni,et al.  Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. , 1992, The Italian journal of gastroenterology.

[56]  V. Shyamala,et al.  Serum hepatitis C virus (HCV)‐RNA and response to alpha‐interferon in anti‐HCV positive chronic hepatitis , 1992, Journal of medical virology.

[57]  Motohiro Shibata,et al.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon‐α therapy: Relationship to genotypes of hepatitis C virus , 1992, Hepatology.

[58]  Koichi Kanai,et al.  HCV genotypes in chronic hepatitis C and response to interferon , 1992, The Lancet.

[59]  J. Esteban,et al.  Interferon‐α in acute posttransfusion hepatitis C:. A randomized, controlled trial , 1992 .

[60]  O. Yokosuka,et al.  Resolution of acute hepatitis C after therapy with natural beta interferon , 1991, The Lancet.

[61]  A. Craxì,et al.  Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. , 1991, Journal of hepatology.

[62]  K. Ohnishi,et al.  Interferon therapy for acute posttransfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status. , 1991, The American journal of gastroenterology.

[63]  A. Alberti,et al.  Pilot study of interferon alpha-2a therapy in preventing chronic evolution of acute hepatitis C , 1990 .